2026VESALIUS-CVIn 12,257 patients at high cardiovascular risk without prior myocardial infarction or stroke, evolocumab reduced major adverse cardiovascular events compared with placebo.
2026Lp(a)HORIZONLipoprotein(a)In 8,323 patients with established cardiovascular disease and Lp(a) ≥70 mg/dL, pelacarsen 80 mg monthly did not reduce cardiovascular death, myocardial infarction, stroke or urgent revascularisation compared with placebo.
2023CLEAR OutcomesNon-statin LDLIn 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.
2019REDUCE-ITTriglyceridesIn 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.
2018ODYSSEY OUTCOMESPCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).
2017FOURIERPCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.
2017CANTOSAnti-inflammatoryIn 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.
2015IMPROVE-ITNon-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.
2008JUPITERStatinsIn 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.
2004PROVE-ITStatinsIn 4,162 patients after acute coronary syndrome, intensive atorvastatin 80 mg reduced death or major cardiovascular events compared with moderate pravastatin 40 mg (16% relative reduction, P=0.005).
19944SStatinsIn 4,444 patients with CAD and total cholesterol 5.5–8.0 mmol/L, simvastatin reduced all-cause mortality compared with placebo.